Basket Study at Providence Medical Group

Basket studies are a novel design in oncology clinical trials that test the effect of a drug targeting a specific mutation or molecular alteration across multiple cancer types. Unlike traditional clinical trials that focus on a single cancer type, basket studies group patients based on the presence of a particular biomarker, regardless of where the cancer originated in the body.

Key features of basket studies include:

  1. Biomarker-driven approach
  2. Multiple cancer types in one trial
  3. Usually single-arm design
  4. Potential for faster drug development

These studies are particularly useful for rare cancers and for evaluating targeted therapies. They can provide valuable insights into the efficacy of a treatment across various tumor types that share a common genetic alteration.

Providence Medical Group is currently enrolling patients for the following basket studies:

Study to test a new drug in participants with advanced or metastatic ovarian, endometrial or HER2-breast cancer

Treatment agent: AZD8205- a B7-H4 targeted antibody drug conjugate (ADC).
Physician: Ian Anderson, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA

A study of Dato-Dxd as monotherapy and in combination with anti-cancer agents in patients with advanced solid tumors: AZ D926UC00001 Tropion Pan-Tumor 03.​

Treatment agent: Datopotamab Deruxtecan- an ADC comprised of a recombinant humanized anti-TROP2 IgG1 mAb
Physician: Yao Yao Pollock, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 (SGN005)​

Treatment agent: Disitamab Vedotin, antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2)
Physician: Ian Anderson, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: https://classic.clinicaltrials.gov/ct2/show/NCT06003231
Sponsor: Seagen Inc.
Location: Providence Cancer Center Santa Rosa, CA

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)​

Treatment agent: Repotrectinib (TPX-0005) oral medication
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://www.clinicaltrials.gov/study/NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Location: Providence Cancer Center Santa Rosa, CA

Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)​

Treatment agent: PRO1184, a folate receptor alpha (FRα) targeted antibody-drug conjugate
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT05579366
Sponsor: ProfoundBio / Precision for Medicine
Location: Providence Cancer Center Santa Rosa, CA

Study for participants with selected HER2 expressing tumors: biliary tract, bladder, endometrial, ovarian, pancreatic, and rare tumors (Destiny Pan-Tumor 2)

Treatment agent: trastuzumab deruxtecan (T-DXd)
Physician: Dr Ian Anderson
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA